BioCardia Inc (NASDAQ: BCDA) reported a quarterly loss of $(0.13) per share for the second quarter ended June 30, 2026, outperforming market expectations. The figure beat the analyst consensus estimate of $(0.18) by 27.78%, reflecting disciplined cost management amid active clinical development. The company’s net loss contracted to $1.6 million from $2.0 million in the same period last year, a 21.3% year-over-year improvement driven primarily by lower research and development expenses.

The financial results coincide with three critical regulatory developments. Japan’s Pharmaceutical and Medical Device Agency (PMDA) confirmed it supports the pre-market regulatory submission for BioCardia’s CardiAMP Cell Therapy for ischemic heart failure, targeting a filing in the fourth quarter of 2026. Simultaneously, the U.S. Food and Drug Administration (FDA) indicated that data from the ongoing CardiAMP HF II trial may be sufficient for Premarket Approval (PMA) in the United States. Additionally, the FDA stated that DeNovo approval is possible for the Helix transendocardial delivery catheter.

Financial Performance

Research and development expenses decreased to $0.9 million for the quarter from $1.4 million in June 2025, largely due to the close-out of the initial CardiAMP HF Trial. This reduction was partially offset by early enrollment costs for the CardiAMP HF II Trial and regulatory activities in Japan. Selling, general, and administrative (SG&A) expenses remained stable at $0.7 million, consistent with the prior year period.

Net cash used in operations increased slightly to $1.7 million from $1.6 million year-over-year, attributed to the timing of supplier payments. During the quarter, BioCardia raised net proceeds of approximately $4.9 million under its "At the Market" facility. The company ended the period with cash and cash equivalents totaling $4.1 million, providing an anticipated runway into 2027.

What the Numbers Show

The divergence between the reported EPS and the consensus estimate highlights a notable beat in profitability metrics. While the company remains in a loss position, the 27.78% beat against the estimate suggests that operational costs were lower or revenues were higher than anticipated by analysts. Furthermore, the 67.5% year-over-year reduction in losses indicates a consistent improvement trend from the previous year’s $(0.40) per share loss to the current $(0.13) per share loss.

Business Highlights

• CardiAMP in Japan: The PMDA Consultation Record confirms alignment on remaining questions for regulatory approval for ischemic HFrEF patients. BioCardia is preparing the electronic trial master file and conducting third-party audits to meet PMDA standards for the Q4 2026 submission.
• CardiAMP in the US: Four clinical sites are actively recruiting for the CardiAMP HF II trial. FDA minutes confirm that this ongoing trial may support PMA for market clearance.
• Helix Delivery System: Following a May pre-submission meeting, BioCardia anticipates submitting follow-on advice to enable Helix approval via the DeNovo pathway.
• Heart3D Imaging: A Japanese patent was allowed for Heart3D Fusion Imaging software, which aids in treatment planning and real-time navigation during procedures.

The data reflects a clear contraction in losses, both against expectations and historical performance. With no other financial metrics disclosed in the source, the focus remains on this significant narrowing of the per-share deficit alongside tangible progress toward commercialization pathways in key markets.

BioCardia, Inc., a developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, will report its financial results for the second quarter of 2026 and provide a corporate update on Wednesday, August 12, 2026. The conference call is scheduled for 4:30 PM EDT and will feature formal remarks from management followed by a question-and-answer session. This disclosure ensures investors have timely access to the company’s latest operational and financial performance data.

The company has provided multiple avenues for participation to accommodate global investors. Registered participants will receive their dial-in numbers upon registration. For those who have not registered, interested parties within the U.S. can call 1-833-316-0559, while international callers should use 1-412-317-5730. All callers are advised to dial in approximately 10 minutes prior to the scheduled start time and request to join the BioCardia call. The event will also be available through a live webcast.

Access Details

Following the live event, a webcast replay of the call will be available approximately one hour after the conclusion of the session. The replay will remain accessible until November 12, 2026. A telephonic replay will also be offered for domestic and Canadian callers at 1-855-669-9658 (toll free) and for international callers at 1-412-317-0088. The access code for the telephonic replay is 3063624.

BioCardia, headquartered in Sunnyvale, California, focuses on developing biotherapeutic platforms for heart disease treatment. Its primary platforms include CardiAMP autologous and CardiALLO allogeneic cell therapies. These therapies are supported by the Helix biotherapeutic delivery platform, the Morph vascular navigation product platform, and the upcoming Heart 3D fusion imaging platform. The company selectively partners with peers developing important biological therapies to advance its pipeline.

For further information, investors may contact David McClung, Chief Financial Officer, at investors@biocardia.com or Miranda Peto from Investor Relations at mpeto@biocardia.com . Both contacts can be reached at (650) 226-0120.